In Australia, Nosinassen Sodium Injection was included in the local Pharmaceutical Benefits Program (PBS) on June 1, 2018 for the treatment of spinal muscular atrophy type 1, type 2 and type 3a patients under 18 years of age.
According to PBS regulations, patients need to pay a certain amount for the subsidized drugs in the plan. From January 1, 2020, patients (holding an Australian health insurance card) will only need to pay up to $41 for most PBS drugs, and if they have a concession card, they will only need to pay $6.60.